Chronic Kidney Disease: Epidemiology Report and Forecast to 2035
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
Analyze chronic kidney disease epidemiology across the 7MM with 10-year forecasts for prevalent and diagnosed cases by age, sex, stage, dialysis status, and comorbidities.
Why Does Chronic Kidney Disease Epidemiology Matter?
Chronic kidney disease (CKD), also known as chronic renal disease, is characterized by a gradual loss of kidney function over time. As CKD progresses, the accumulation of fluid and waste in the body can worsen and eventually lead to kidney failure. The glomerular filtration rate (GFR) is a key measure of kidney function and is used in the diagnosis and classification of CKD.
Across the seven major pharmaceutical markets (7MM), total prevalent cases of CKD are expected to increase from 118,878,006 cases in 2025 to 129,339,791 cases in 2035, representing an annual growth rate (AGR) of 0.88%. Diagnosed prevalent cases are expected to increase from 23,472,472 cases in 2025 to 25,418,095 cases in 2035, at an AGR of 0.83%.
This report provides a 10-year epidemiological forecast across the US, France, Germany, Italy, Spain, the UK, and Japan, with detailed segmentation by age, sex, disease stage, dialysis dependence, and key comorbidities.
You can use this report to:
- Assess the current and forecast CKD patient population across the 7MM
- Track total prevalent and diagnosed prevalent CKD cases through 2035
- Compare CKD epidemiology across the seven major pharmaceutical markets
- Identify patient populations by age and sex
- Analyze CKD cases by disease stage
- Assess dialysis-dependent and non-dialysis-dependent diagnosed patients
- Understand CKD prevalence among patients with hypertension, diabetes, and cardiovascular disease
- Identify markets and demographic groups relevant to CKD therapeutics
- Support product design, pricing, and launch planning
- Inform sales and marketing strategies using detailed epidemiological data
Key Insights in the Chronic Kidney Disease Epidemiology Landscape
The report highlights key developments in CKD epidemiology across the 7MM:
- Total prevalent cases of CKD across the 7MM are forecast to increase from 118,878,006 in 2025 to 129,339,791 in 2035.
- Total prevalent cases are forecast to grow at an AGR of 0.88% during 2025–2035.
- Diagnosed prevalent cases are forecast to increase from 23,472,472 in 2025 to 25,418,095 in 2035.
- Diagnosed prevalent cases are forecast to grow at an AGR of 0.83%.
- In 2035, the US is expected to have the highest number of total prevalent CKD cases in the 7MM, at 44,637,257 cases.
- Italy is expected to have the fewest total prevalent CKD cases in 2035, at 3,866,846 cases.
- In 2035, Japan is expected to have the highest number of diagnosed prevalent CKD cases in the 7MM, at 5,852,016 cases.
- Italy is expected to have the fewest diagnosed prevalent CKD cases in 2035, at 957,683 cases.
- GlobalData epidemiologists attribute the projected increase in total and diagnosed prevalent CKD cases to changes in population dynamics and diagnosis rates across individual markets.
- CKD cases are segmented by disease stage, from stage I through stage V.
- Diagnosed prevalent cases are segmented into dialysis-dependent and non-dialysis-dependent populations.
- The model also provides diagnosed prevalent cases by key comorbidities including hypertension, diabetes, and cardiovascular disease (CVD).
Scope
What Will You Learn from This Chronic Kidney Disease Epidemiology Analysis Report?
This report provides insight into:
- The epidemiology of chronic kidney disease across the 7MM
- Historical CKD trends
- 10-year forecasts for total prevalent CKD cases
- 10-year forecasts for diagnosed prevalent CKD cases
- CKD prevalence by country
- CKD cases by age group
- CKD cases by sex
- CKD cases by disease stage
- Stage I, II, IIIa, IIIb, IV, and V CKD populations
- Dialysis-dependent CKD populations
- Hemodialysis and peritoneal dialysis populations
- Non-dialysis-dependent CKD populations
- CKD populations with hypertension
- CKD populations with diabetes
- CKD populations with cardiovascular disease
- Changes in population dynamics affecting CKD prevalence
- Diagnosis-rate trends across the 7MM
- Market-specific patient population opportunities for CKD therapeutics
Who Should Buy This Chronic Kidney Disease Epidemiology Analysis Report?
This report may be valuable for:
- Pharmaceutical companies
- Biotechnology companies
- Medical device companies
- Nephrology-focused therapeutics companies
- Drug development teams
- Clinical development teams
- Commercial strategy teams
- Market access teams
- Pricing and reimbursement teams
- Sales and marketing teams
- Business development teams
- Healthcare investors
- Competitive intelligence teams
- Epidemiology and market research teams
- Senior pharmaceutical decision-makers
How Companies Use This Chronic Kidney Disease Epidemiology Analysis
Pharmaceutical and healthcare companies can use this report to:
- Quantify CKD patient populations across the 7MM
- Forecast changes in total and diagnosed prevalence
- Identify markets with significant CKD patient populations
- Analyze patient populations by age and sex
- Assess patient populations by CKD stage
- Identify dialysis-dependent and non-dialysis-dependent populations
- Assess CKD populations with key comorbidities
- Support product design and development decisions
- Inform pricing and launch planning
- Identify age groups relevant to CKD therapeutics
- Organize sales and marketing activities
- Compare epidemiological trends across the 7MM
- Support commercial opportunity assessment
- Develop business strategies based on CKD epidemiological trends
Reasons to Buy
Benchmark the Global Chronic Kidney Disease Epidemiology Landscape
The report enables stakeholders to benchmark CKD epidemiology across the seven major pharmaceutical markets:
- US
- France
- Germany
- Italy
- Spain
- UK
- Japan
The analysis provides comparison across:
- Total prevalent cases
- Diagnosed prevalent cases
- Age groups
- Sex
- CKD stages
- Dialysis dependence
- Hypertension
- Diabetes
- Cardiovascular disease
The consistent forecast methodology across the 7MM supports meaningful comparison of diagnosed prevalent CKD cases across the covered markets.
Built on GlobalData Epidemiology Intelligence
The CKD epidemiology forecast is supported by data obtained from peer-reviewed articles and population-based studies.
GlobalData’s epidemiologists apply a consistent methodology across the seven major pharmaceutical markets, providing a structured 10-year forecast of total and diagnosed prevalent CKD cases and enabling cross-market comparison.
Act Now to Identify Opportunities in the Chronic Kidney Disease Market
Understanding the size and composition of the CKD patient population can support pharmaceutical companies in assessing therapeutic opportunities, product strategies, and market planning.
Use this report to quantify CKD prevalence through 2035, assess patient populations by age, sex, stage, dialysis status, and comorbidities, compare the 7MM, and identify demographic and market opportunities for CKD therapeutics.
Table of Contents
Table
Figures
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Sample Report
Chronic Kidney Disease: Epidemiology Report and Forecast to 2035 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:
- Assess the relevance of the report
- Evaluate the quality of the report
- Justify the cost
Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.
